Cargando…
Rituximab Selectively Suppresses Specific Islet Antibodies
OBJECTIVE: The TrialNet Study Group evaluated rituximab, a B-cell–depleting monoclonal antibody, for its effect in new-onset patients with type 1A diabetes. Rituximab decreased the loss of C-peptide over the first year of follow-up and markedly depleted B lymphocytes for 6 months after administratio...
Autores principales: | Yu, Liping, Herold, Kevan, Krause-Steinrauf, Heidi, McGee, Paula L., Bundy, Brian, Pugliese, Alberto, Krischer, Jeff, Eisenbarth, George S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Diabetes Association
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3178300/ https://www.ncbi.nlm.nih.gov/pubmed/21831969 http://dx.doi.org/10.2337/db11-0674 |
Ejemplares similares
-
Glucose and Inflammation Control Islet Vascular Density and β-Cell Function in NOD Mice: Control of Islet Vasculature and Vascular Endothelial Growth Factor by Glucose
por: Akirav, Eitan M., et al.
Publicado: (2011) -
Donor Islet Endothelial Cells in Pancreatic Islet Revascularization
por: Nyqvist, Daniel, et al.
Publicado: (2011) -
Markedly Decreased Blood Perfusion of Pancreatic Islets Transplanted Intraportally Into the Liver: Disruption of Islet Integrity Necessary for Islet Revascularization
por: Henriksnäs, Johanna, et al.
Publicado: (2012) -
Increased Numbers of Low-Oxygenated Pancreatic Islets After Intraportal Islet Transplantation
por: Olsson, Richard, et al.
Publicado: (2011) -
Distinguishing Persistent Insulin Autoantibodies With Differential Risk: Nonradioactive Bivalent Proinsulin/Insulin Autoantibody Assay
por: Yu, Liping, et al.
Publicado: (2012)